

Re.Denosumab MTA

I would make the following comments;

1. I consider that all the relevant information has been taken into account.
2. I consider all the summaries of clinical and cost effectiveness to be reasonable interpretations of the evidence.
3. I consider the provisional recommendations to be sound and a suitable basis for guidance to the NHS with the following caveat:

1.1 and 1.2:

While I accept that these recommendations are based on the published evidence including the NICE Prostate Cancer guidance there is a difference between the 2 tumour sites which could be (wrongly) attributed to discrimination. I would be keen to see acknowledgment of future modification to the guidelines in light of further evidence in Prostate cancer.

4. I can see no issue relating to potential discrimination on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?

Yours Sincerely

Dr.David Dodds